CC
BBOT

Commodore Capital’s BridgeBio Oncology BBOT Stock Holding History

Commodore Capital’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500,000
Closed -$5.25M – 35
2024
Q4 		$5.25M Hold
500,000
– – 0.38% 26
2024
Q3 		$5.22M Hold
500,000
– – 0.33% 33
2024
Q2 		$5.11M Hold
500,000
– – 0.35% 32
2024
Q1 		$5.2M Buy
+500,000
New +$5.18M 0.35% 35

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return

Commodore Capital's BBOT Position: Q1 2025 in Review

Commodore Capital sold out of BridgeBio Oncology (BBOT) in Q1 2025, closing a stake of 500,000 shares — an estimated $5.25M sold.

Commodore Capital first reported a position in BBOT in Q1 2024 and held it in 4 quarters. The position peaked at $5.25M in Q4 2024. 31 funds tracked by Wall St. Rank hold BBOT as of Q1 2025.

  • Commodore Capital reported no remaining BridgeBio Oncology position as of Q1 2025 after selling out during the quarter.
  • Commodore Capital sold 500,000 BridgeBio Oncology shares in Q1 2025, an estimated $5.25M.
  • Commodore Capital first reported a position in BridgeBio Oncology in Q1 2024 and held it in 4 quarters.
  • Commodore Capital's BridgeBio Oncology position peaked at $5.25M in Q4 2024.
  • 31 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2025.

Based on Commodore Capital's 13F filing for Q1 2025, filed 15 May 2025.